<--- Back to Details
First PageDocument Content
Medicine / Clinical medicine / Immunology / Biology / Immune system / Monoclonal antibodies / Biotechnology / Glycoproteins / Antibody / Cancer immunotherapy / Bispecific monoclonal antibody / Phage display
Date: 2016-08-16 03:53:14
Medicine
Clinical medicine
Immunology
Biology
Immune system
Monoclonal antibodies
Biotechnology
Glycoproteins
Antibody
Cancer immunotherapy
Bispecific monoclonal antibody
Phage display

Cover Conference-at-a-Glance Final Agenda Eighth Annual

Add to Reading List

Source URL: www.giievent.jp

Download Document from Source Website

File Size: 1,71 MB

Share Document on Facebook

Similar Documents

# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim Wi

# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,*,#, Stephen M. Shaw 1,*, Kim Wi

DocID: 1vdls - View Document

Microsoft Word - ST64 Cancer Immunotherapy v1.0.docx

Microsoft Word - ST64 Cancer Immunotherapy v1.0.docx

DocID: 1uTyz - View Document

FALL/WINTERUCSF Oncology Connection Oncologist Lawrence Fong, MD, is leading UCSF’s newly launched Cancer Immunotherapy Program

FALL/WINTERUCSF Oncology Connection Oncologist Lawrence Fong, MD, is leading UCSF’s newly launched Cancer Immunotherapy Program

DocID: 1tGAn - View Document

Cancer Immunotherapy & Personalized Vaccines Alex Rubinsteyn Mount Sinai, Hammer Lab

Cancer Immunotherapy & Personalized Vaccines Alex Rubinsteyn Mount Sinai, Hammer Lab

DocID: 1tBVB - View Document